StockNews.com started coverage on shares of NanoViricides (NYSE:NNVC – Free Report) in a research report released on Tuesday morning. The firm issued a sell rating on the stock.
NanoViricides Price Performance
NYSE:NNVC opened at $1.14 on Tuesday. The firm has a market capitalization of $13.43 million, a P/E ratio of -1.41 and a beta of 0.68. NanoViricides has a 1-year low of $1.00 and a 1-year high of $2.00. The company’s fifty day moving average price is $1.21 and its 200-day moving average price is $1.16.
NanoViricides (NYSE:NNVC – Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Stories
- Five stocks we like better than NanoViricides
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Charles Schwab Fortifies its Uptrend on EPS Beat
- There Are Different Types of Stock To Invest In
- Lockheed Martin Stock Aims for a Fresh All-Time High
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
